Clinical trial NCT02672540: A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients
Official title: A Phase II, Multicenter, Single-Blind, Randomized Study of the Safety and Effectiveness of SANGUINATE™ Versus Normal Saline in Adult Sickle Cell Disease Patients With Vaso-Occlusive Crisis (VOC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Anemia, Sickle Cell
Keywords: Sickle Cell
Anemia
VOC
Vaso occlusive crisis
Lead sponsor: Prolong Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2016-02-03
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Safety and effect of SANGUINATE on Sickle Cell Disease patients experiencing a vaso-occlusive crisis who are admitted to the hospital for treatment.

Detailed description: A single-blind, multicenter, randomized, placebo-control study in which 30 Sickle Cell disease patients having a vaso-occlusive crisis will either receive SANGUINATE 320 mg/kg/patient (8 mL/kg/patient) or Normal Saline on Day 1 (Visit 1) and Day 2 (Visit 2) infused over 2 hours each day. Patients are to remain in the hospital for up to 7 days but can be discharged at any time after receiving the second dose of SANGUINATE, provided their vaso-occlusive crisis has resolved and the patient has completed discharge procedures. Patients will have a follow-up phone call 7 days after discharge from the hospital to obtain safety, concomitant medication and pain assessments.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 and ≤ 65 years of age
2. Diagnosis of Sickle Cell Disease (Hb-SS or any Genotype)
3. Pain-score due to vaso-occlusive pain crisis (VOC) ≥ 8 on a 10 point scale
4. VOC pain location ≥ 1 sites typical of vaso-occlusive crisis
5. Patients with Priapism, acute chest syndrome, and/or with other Sickle Cell Disease comorbidities can be enrolled with good judgment of the Investigator.
6. Signed and dated informed written consent by the subject
7. Able to receive intravenous infusion of SANGUINATE or Normal Saline
8. Women of childbearing potential with a negative serum pregnancy test and using a reliable method of contraception during the study period and for 30 days thereafter. Male study participants also agree to use contraception for 30 days after the study period

Exclusion Criteria:

1. In the judgment of the investigator, the patient is not a good candidate for the study
2. Females who are lactating and/or breastfeeding
3. Fewer than 14 days since prior infusion pain medication treatment for VOC
4. Medical history or evidence of moderate to severe renal insufficiency (estimated GFR \< 60 mL/min) or chronic kidney disease, or of moderate to severe hepatic disease (ALTs \> 5 x ULN)
5. Concurrent or prior treatment within 30 days of Screening with an investigational medication.
6. Symptoms or electrocardiogram (ECG)-based signs of acute myocardial infarction, unstable angina pectoris, decompensated heart failure, third degree heart block or cardiac arrhythmia associated with hemodynamic instability;
7. Severe or unstable concomitant condition or disease (e.g., known significant neurologic deficit, cancer, hematologic, metabolic or coronary disease), or chronic condition (e.g., psychiatric disorder), that, in the opinion of the Investigator, may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results;
8. Evidence or history of regular alcohol abuse
9. Screening laboratory result indicating serologic positivity for hepatitis C antibodies or hepatitis B surface antigens, unless explained by a documented vaccination.
10. Unable to comply with study attendance, protocol procedures or other study requirements;
11. Abnormal Echocardiogram at Study Entry (defined as Tricuspid Regurgitant Jet Velocity \>3.1 m/sec).

Primary outcomes:
measure: Time to readiness for discharge from in hospital stay following treatment with SANGUINATE and Normal Saline.
timeFrame: Up to 7 Days
Secondary outcomes:
measure: Safety of treatment as defined by changes in vital signs, electrocardiographic, biochemical, hematological, and urinalysis measures, as well as reported increases in pain and other reported adverse events
timeFrame: Up to 7 Days
measure: Proportion of patients who develop acute chest syndrome (ACS) during the study.
timeFrame: Up to 14 Days
measure: Proportion of patients who are re-hospitalized for their vaso-occlusive crisis episode.
timeFrame: Up to 7 Days
measure: Total length of stay (LOS) following treatment of SANGUINATE versus Normal Saline.
timeFrame: Up to 7 Days
measure: Percent reduction in total pain medication required during in-hospital stay following treatment with SANGUINATE and Normal Saline.
timeFrame: Up to 7 Days
measure: Percent reduction in pain score utilizing a visual analog scale following treatment with SANGUINATE and Normal Saline.
timeFrame: Up to 7 Days
measure: Reduction in the level of C-Reactive Protein following treatment of SANGUINATE versus Normal Saline.
timeFrame: Up to 7 Days
Other outcomes:
Locations:
city: Bogota
country: Colombia
city: Santo Domingo
country: Dominican Republic
city: San Pedro Sula
country: Honduras
city: Panama City
country: Panama
Study officials:
affiliation: Prolong Pharmaceuticals
name: Hemant Misra, PhD
role: STUDY_DIRECTOR
References: